Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Zacks News
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
by Zacks Equity Research
Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.
Syneos Health (SYNH) Collaborates With uMotif for New Platform
by Zacks Equity Research
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
Zacks.com featured highlights Penumbra, Trip.com, Transportadora de Gas del Sur and Vipshop
by Zacks Equity Research
Penumbra, Trip.com, Transportadora de Gas del Sur and Vipshop have been highlighted in this Screen of The Week article.
Envista (NVST) Gains From New Acquisitions Amid FX Woes
by Zacks Equity Research
Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Medtronic's (MDT) MiniMed 780G System Favored by New Data
by Zacks Equity Research
Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.
Buy These 4 Low-Beta Stocks to Counter the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Trip.com Group (TCOM), Transportadora (TGS) and Vipshop Holdings (VIPS) are poised to gain.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
by Zacks Equity Research
Haemonetics (HAE) receives FDA clearance for the advancements made to the NexSys PCS plasma collection system.
CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs
by Zacks Equity Research
CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.
STERIS (STE) Buys Surgical Instrumentation Platform From BDX
by Zacks Equity Research
STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.
Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches
by Zacks Equity Research
Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
by Zacks Equity Research
NSPCA is also working on recommending SenesTech's (SNES) ContraPest to private and state entities and to assist with regulatory issues.
Insulet (PODD) Launches the Omnipod 5 AID System in the UK
by Zacks Equity Research
Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.
Why You Should Retain Walgreens Boots (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection
by Zacks Equity Research
The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.